92 related articles for article (PubMed ID: 25727515)
1. A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.
Mastoraki S; Chimonidou M; Dimitrakopoulos L; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Chim Acta; 2015 Apr; 444():303-9. PubMed ID: 25727515
[TBL] [Abstract][Full Text] [Related]
2. A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples.
Dimitrakopoulos L; Vorkas PA; Georgoulias V; Lianidou ES
BMC Cancer; 2012 Oct; 12():486. PubMed ID: 23088560
[TBL] [Abstract][Full Text] [Related]
3. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsaroucha E; Kakolyris S; Georgoulias V; Lianidou E
Clin Chem Lab Med; 2016 Aug; 54(8):1385-93. PubMed ID: 26741346
[TBL] [Abstract][Full Text] [Related]
4. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.
Chimonidou M; Strati A; Malamos N; Georgoulias V; Lianidou ES
Clin Chem; 2013 Jan; 59(1):270-9. PubMed ID: 23136251
[TBL] [Abstract][Full Text] [Related]
5. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
[TBL] [Abstract][Full Text] [Related]
6. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
Balgkouranidou I; Karayiannakis A; Matthaios D; Bolanaki H; Tripsianis G; Tentes AA; Lianidou E; Chatzaki E; Fiska A; Lambropoulou M; Kolios G; Kakolyris S
Clin Chem Lab Med; 2013 Jul; 51(7):1505-10. PubMed ID: 23403728
[TBL] [Abstract][Full Text] [Related]
7. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
[TBL] [Abstract][Full Text] [Related]
8. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
9. Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer.
Liu W; Guan M; Su B; Li J; Ma W; Liu C; Li M; Lin Y; Lu Y
Clin Chim Acta; 2010 Jul; 411(13-14):940-6. PubMed ID: 20227403
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.
Chimonidou M; Strati A; Tzitzira A; Sotiropoulou G; Malamos N; Georgoulias V; Lianidou ES
Clin Chem; 2011 Aug; 57(8):1169-77. PubMed ID: 21700955
[TBL] [Abstract][Full Text] [Related]
11. Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM.
Kristensen LS; Wojdacz TK; Thestrup BB; Wiuf C; Hager H; Hansen LL
BMC Cancer; 2009 Dec; 9():453. PubMed ID: 20025721
[TBL] [Abstract][Full Text] [Related]
12. SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer.
Yin D; Jia Y; Yu Y; Brock MV; Herman JG; Han C; Su X; Liu Y; Guo M
Discov Med; 2012 Jul; 14(74):33-40. PubMed ID: 22846201
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer.
Jia Y; Yang Y; Zhan Q; Brock MV; Zheng X; Yu Y; Herman JG; Guo M
J Mol Diagn; 2012 Nov; 14(6):577-85. PubMed ID: 22921431
[TBL] [Abstract][Full Text] [Related]
14. Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome.
Fan R; Zhao XL; Wang H; He HY; Peng ZP; Yang B; Han T; Wang W; Wang XQ; Lin GW
Clin Lab; 2014; 60(9):1465-74. PubMed ID: 25291942
[TBL] [Abstract][Full Text] [Related]
15. SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma.
Jia Y; Yang Y; Liu S; Herman JG; Lu F; Guo M
Epigenetics; 2010; 5(8):743-9. PubMed ID: 20716954
[TBL] [Abstract][Full Text] [Related]
16. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
Kioulafa M; Balkouranidou I; Sotiropoulou G; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Int J Cancer; 2009 Dec; 125(12):2887-92. PubMed ID: 19551853
[TBL] [Abstract][Full Text] [Related]
17. Closed-tube PCR methods for locus-specific DNA methylation analysis.
Candiloro IL; Mikeska T; Dobrovic A
Methods Mol Biol; 2011; 791():55-71. PubMed ID: 21913071
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different promoter methylation assays in breast cancer.
Suijkerbuijk KP; Pan X; van der Wall E; van Diest PJ; Vooijs M
Anal Cell Pathol (Amst); 2010; 33(3):133-41. PubMed ID: 20978321
[TBL] [Abstract][Full Text] [Related]
19. 5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1.
Li W; Wu D; Niu Z; Jiang D; Ma H; He H; Zuo X; Xie X; He Y
Int J Mol Med; 2016 Oct; 38(4):1047-54. PubMed ID: 27513557
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of RASSF1A promoter methylation in operable breast cancer.
Kioulafa M; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Clin Biochem; 2009 Jul; 42(10-11):970-5. PubMed ID: 19374895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
